Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Dexamethasone in Relapsed/Refractory Myeloma with Renal Impairment
NCT03450057Phase 2Completed
- Sponsor
- Hellenic Society of Hematology
- Start
- Feb 2018
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Started Feb 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03450057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450057.